Regulatory approval

Published by the Health Service Executive. Approved

Nivolumab in combination with ipilimumab for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer (MSI-H mCRC) after prior fluoropyrimidine-based combination chemotherapy.

This is written in the approval document.

Reimbursement

ODMS

Citation

Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6385/551_Nivolumab_3mgkg_Ipilimumab_1mgk.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
HSE (1) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab